Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 3 | 4 |
| 1.1 List of Tables | 6 | 1 |
| 1.2 List of Figures | 6 | 1 |
| 2 Nanotechnology in Drug Delivery Introduction | 7 | 2 |
| 2.1 Introduction | 7 | 1 |
| 2.2 GBI Research Report Guidance | 8 | 1 |
| 3 Application of Nanotechnology in Drug Delivery | 9 | 4 |
| Current Applications of Nano-enabled Drug Delivery | 9 | 1 |
| 3.1.1 Nano-engineered drugs | 9 | 1 |
| 3.1.1.1 Nano Crystals | 9 | 1 |
| 3.1.1.2 Nano Suspensions | 9 | 1 |
| 3.1.2 Nano-carriers | 10 | 1 |
| 3.1.2.1 Carbon and Ceramic Nanostructures | 10 | 1 |
| 3.1.2.2 Dendrimers | 10 | 1 |
| 3.1.2.3 Liposomes | 10 | 1 |
| 3.1.2.4 Micelles and Polymeric Nanoparticles | 10 | 1 |
| 3.2 Future Applications of Nano-enabled Drug Delivery | 11 | 1 |
| Gene and Vaccine Delivery | 11 | 1 |
| 3.2.2 Controlled-Release Devices | 12 | 1 |
| Increased Biocompatibility | 12 | 1 |
| 3.2.4 Improved Drug Bioavailability and Solubility | 12 | 1 |
| 3.2.5 Applied Diagnosis, Etiology, Prognosis and Therapy (ADEPT) | 12 | 1 |
| 3.2.6 Tissue Specific Delivery | 12 | 1 |
| 4 Nanotechnology in Drug Delivery Case Studies | 13 | 3 |
| 4.1 Abraxis Bioscience, Inc. Paclitaxel-Albumin Nanoparticles (Abraxane) | 13 | 1 |
| 4.2 Nanospectra Biosciences AuroShell Particles | 13 | 1 |
| 4.3 Calando Pharmaceuticals, Inc. RONDEL Technology | 13 | 1 |
| 4.4 Starpharma Holdings, Ltd. Dendrimer-Based VivaGel | 14 | 1 |
| 4.5 Mersana Therapeutics: Fleximer Camptothecin Conjugate | 14 | 1 |
| Elan Corporation NanoCrystal Technology | 14 | 2 |
| 5 Nanotechnology in Drug Delivery Market Characterization | 16 | 24 |
| 5.1 Introduction | 16 | 1 |
| 5.2 Nano-enabled Drug Delivery Market Drivers | 16 | 1 |
| 5.2.1 Clinical Benefits of Nano-enabled Drug delivery | 16 | 1 |
| Value Addition to Existing Pharmaceutical Products through Reformulation | 16 | 1 |
| 5.2.3 Strong Pipeline Portfolio | 16 | 1 |
| Nano-Enabled Drug Delivery Market Barriers | 17 | 1 |
| 5.3.1 Poor R&D Facilities and Time Gap between Research and Commercialization | 17 | 1 |
| 5.3.2 Lack of Consistent Policy on Technology Transfer and Lack of Capacity to Produce Products | 17 | 1 |
| 5.3.3 Regulatory Hindrance | 17 | 1 |
| 5.4 Opportunity and Unmet Need Drug Delivery | 18 | 1 |
| 5.4.1 Opportunities | 18 | 1 |
| 5.4.1.1 Opportunities for New Drug Delivery Company | 18 | 1 |
| 5.4.1.2 Higher Growth Potential for Nano-Enabled Drugs | 18 | 1 |
| 5.4.1.3 Licensing Opportunity | 18 | 1 |
| Unmet Need | 18 | 1 |
| 5.4.2.1 Toxicity of Nanomaterials | 18 | 1 |
| 5.4.2.2 Need to Understand Biological Behavior and Distribution Patterns of Nanomaterials | 19 | 1 |
| 5.5 Selected Nano-Enabled Therapeutics Approved by the FDA | 20 | 1 |
| 5.5.1 Doxil (Caelyx) | 20 | 1 |
| 5.5.1.1 Overview | 20 | 1 |
| 5.5.1.2 Mechanism of Action | 20 | 1 |
| 5.5.1.3 Clinical Trial Details | 20 | 1 |
| 5.5.2 Abraxane | 21 | 1 |
| 5.5.2.1 Overview | 21 | 1 |
| 5.5.2.2 Mechanism of Action | 21 | 1 |
| 5.5.2.3 Clinical Trial Details | 21 | 1 |
| 5.5.3 AmBisome | 22 | 1 |
| 5.5.3.1 Overview | 22 | 1 |
| 5.5.3.2 Mechanism of Action | 22 | 1 |
| 5.5.3.3 Clinical Trial Details | 22 | 1 |
| 5.5.4 Diprivan | 23 | 1 |
| 5.5.4.1 Overview | 23 | 1 |
| 5.5.4.2 Mechanism of Action | 23 | 1 |
| 5.5.4.3 Clinical Trial Details | 23 | 1 |
| 5.5.5 Triglide | 24 | 1 |
| 5.5.5.1 Overview | 24 | 1 |
| 5.5.5.2 Mechanism of Action | 24 | 1 |
| 5.5.5.3 Clinical Trial Details | 25 | 1 |
| 5.5.6 Myocet | 25 | 1 |
| 5.5.6.1 Overview | 25 | 1 |
| 5.5.6.2 Mechanism of Action | 25 | 1 |
| 5.5.6.3 Clinical Trial Details | 25 | 1 |
| 5.5.7 DepoCyt | 26 | 1 |
| 5.5.7.1 Overview | 26 | 1 |
| 5.5.7.2 Mechanism of Action | 26 | 1 |
| 5.5.7.3 Clinical Trial Details | 26 | 1 |
| 5.5.8 DaunoXome | 27 | 1 |
| 5.5.8.1 Overview | 27 | 1 |
| 5.5.8.2 Mechanism of Action | 27 | 1 |
| 5.5.8.3 Clinical Trial Details | 27 | 1 |
| Estrasorb | 27 | 1 |
| 5.5.9.1 Overview | 27 | 1 |
| 5.5.9.2 Mechanism of Action | 28 | 1 |
| 5.5.9.3 Clinical Trial Details | 28 | 1 |
| 5.5.10 Macugen | 28 | 1 |
| 5.5.10.1 Overview | 28 | 1 |
| 5.5.10.2 Mechanism of Action | 28 | 1 |
| 5.5.10.3 Clinical Trial Details | 28 | 1 |
| 5.5.11 Abelcet | 29 | 1 |
| 5.5.11.1 Overview | 29 | 1 |
| 5.5.11.2 Mechanism of Action | 29 | 1 |
| 5.5.12 Adagen | 30 | 1 |
| 5.5.12.1 Overview | 30 | 1 |
| 5.5.12.2 Mechanism of Action | 30 | 1 |
| Pegasys | 30 | 1 |
| 5.5.13.1 Overview | 30 | 1 |
| 5.5.13.2 Mechanism of Action | 30 | 1 |
| 5.5.13.3 Clinical Trial Details | 30 | 2 |
| 5.5.14 Somavert | 32 | 1 |
| 5.5.14.1 Overview | 32 | 1 |
| 5.5.14.2 Mechanism of Action | 32 | 1 |
| 5.5.14.3 Clinical Trial Details | 32 | 1 |
| Neulasta | 33 | 1 |
| 5.5.15.1 Overview | 33 | 1 |
| 5.5.15.2 Mechanism of Action | 33 | 1 |
| 5.5.15.3 Clinical Trial Details | 33 | 1 |
| 5.5.16 Copaxone | 34 | 1 |
| 5.5.16.1 Overview | 34 | 1 |
| 5.5.16.2 Mechanism of Action | 34 | 1 |
| 5.5.16.3 Clinical Trial Details | 34 | 1 |
| 5.5.17 Amphotec | 35 | 1 |
| 5.5.17.1 Overview | 35 | 1 |
| 5.5.17.2 Mechanism of Action | 35 | 1 |
| 5.5.17.3 Clinical Trial Details | 35 | 1 |
| 5.5.18 PegIntron | 35 | 1 |
| 5.5.18.1 Overview | 35 | 1 |
| 5.5.18.2 Mechanism of Action | 36 | 1 |
| 5.5.18.3 Clinical Trial Details | 36 | 1 |
| 5.5.19 Oncaspar | 37 | 1 |
| 5.5.19.1 Overview | 37 | 1 |
| 5.5.19.2 Mechanism of Action | 37 | 1 |
| 5.5.19.3 Clinical Trial Details | 37 | 1 |
| Epaxal | 38 | 1 |
| 5.5.20.1 Overview | 38 | 1 |
| 5.5.20.2 Mechanism of Action | 38 | 1 |
| 5.5.20.3 Clinical Trial Details | 38 | 1 |
| Elestrin | 38 | 1 |
| 5.5.21.1 Overview | 38 | 1 |
| 5.5.21.2 Mechanism of Action | 38 | 1 |
| 5.5.21.3 Clinical trial details | 39 | 1 |
| 6 Nanotechnology in Drug Delivery Trend Analysis | 40 | 2 |
| 6.1 Increasing Government Funding for Nanotechnology R&D | 40 | 1 |
| 6.2 Increasing Seed and Early-Stage Venture Capital | 40 | 1 |
| 6.3 Creation of a New Registration Category for Nanotechnology Products within the USPTO | 40 | 1 |
| 6.4 Genericization and Emerging Business Models Driving a Need for Novel Drug Delivery Methods | 41 | 1 |
| 7 Nanotechnology in Drug Delivery Regulatory Landscape | 42 | 7 |
| Introduction | 42 | 2 |
| 7.2 Europe | 44 | 1 |
| 7.2.1 REACH Regulation | 44 | 2 |
| 7.2.2 European Medicines Agency | 46 | 1 |
| The US | 46 | 1 |
| 7.3.1 Environment Protection Agency | 46 | 1 |
| 7.3.2 Food and Drug Administration | 47 | 1 |
| 7.3.3 National Institute of Occupational Safety and Health | 47 | 1 |
| 7.4 Japan | 48 | 1 |
| 8 Nanotechnology in Drug Delivery Pipeline Analysis | 49 | 6 |
| Overview | 49 | 1 |
| 8.1.1 Pipeline Analysis by Phase | 50 | 1 |
| 8.1.1.1 Nano-Enabled Drug Delivery Systems Regulatory Filing Stage | 50 | 1 |
| 8.1.1.2 Nano-enabled Drug Delivery Systems Phase III Clinical Pipeline | 51 | 1 |
| 8.1.1.3 Nano-enabled Drug Delivery Systems Phase II Clinical Pipeline | 51 | 1 |
| 8.1.1.4 Nano-enabled Drug Delivery Systems Phase I Clinical Pipeline | 52 | 1 |
| 8.1.1.5 Nano-enabled Drug Delivery Systems Preclinical pipeline | 53 | 1 |
| 8.1.1.6 Nano-enabled Drug Delivery Systems Discovery Pipeline | 54 | 1 |
| 9 Nanotechnology in Drug Delivery Strategic Consolidations | 55 | 10 |
| Overview | 55 | 1 |
| 9.2 Mergers and Acquisitions | 55 | 1 |
| 9.2.1 Mergers and Acquisitions by Geography | 55 | 1 |
| 9.2.2 Mergers and Acquisitions by Deal value | 56 | 1 |
| 9.2.3 Mergers and Acquisition Analysis by Deal Type | 57 | 1 |
| 9.3 Summary of Major M&A Deals | 58 | 1 |
| 9.3.1 AstraZeneca Acquires MedImmune | 58 | 1 |
| 9.3.2 Pfizer Completes Acquisition of Wyeth | 58 | 1 |
| 9.3.3 Celgene Announces To Acquire Abraxis BioScience | 58 | 1 |
| 9.3.4 Amgen Acquires Abgenix | 59 | 1 |
| 9.3.5 Teva Pharmaceutical Acquires Ivax | 59 | 1 |
| 9.4 Licensing Agreement | 60 | 1 |
| 9.4.1 Deals by Year of Consolidations | 60 | 1 |
| 9.4.2 Deals by Geography | 61 | 1 |
| 9.4.3 Deals by Deal value | 62 | 1 |
| 9.5 Summary of Major M&A Deals | 62 | 1 |
| 9.5.1 AstraZeneca Enters Into Collaboration and Licensing Agreement with Targacept | 62 | 1 |
| 9.5.2 AstraZeneca Enters into Licensing Agreement with Rigel Pharmaceuticals | 63 | 1 |
| 9.5.3 Isis Pharmaceuticals Enters Into Licensing Agreement with Genzyme | 63 | 1 |
| 9.5.4 Nektar Therapeutics Enters Into Licensing Agreement with AstraZeneca | 63 | 1 |
| 9.5.5 Abraxis Enters Into License Agreement With ProMetic Life Sciences | 64 | 1 |
| 10 Nanotechnology in Drug Delivery Future Players | 65 | 9 |
| Overview | 65 | 1 |
| 10.2 Abraxis Bioscience (Abraxis) | 66 | 1 |
| 10.2.1 Overview | 66 | 1 |
| 10.2.2 Business Description | 66 | 1 |
| 10.2.3 Product Portfolio | 67 | 1 |
| 10.3 AlphaRx Corporation | 68 | 1 |
| 10.3.1 Overview | 68 | 1 |
| 10.3.2 Business Description | 68 | 1 |
| 10.3.3 Product Portfolio | 69 | 1 |
| 10.4 Camurus AB | 69 | 1 |
| 10.4.1 Overview | 69 | 1 |
| 10.4.2 Product Portfolio | 70 | 1 |
| 10.5 Eurand | 70 | 1 |
| 10.5.1 Overview | 70 | 1 |
| 10.5.2 Business Description | 70 | 1 |
| 10.5.3 Product Portfolio | 71 | 1 |
| 10.6 NanoBio Corporation | 71 | 1 |
| 10.6.1 Overview | 71 | 1 |
| 10.6.2 Product Portfolio | 72 | 1 |
| 10.7 NanoCarrier | 72 | 1 |
| 10.7.1 Overview | 72 | 1 |
| 10.7.2 Product Portfolio | 73 | 1 |
| 11 Nanaotechnology in Drug Delivery Appendix | 74 | 4 |
| 11.1 Market Definitions | 74 | 1 |
| 11.2 Abbreviations | 74 | 1 |
| 11.3 Research Methodology | 75 | 3 |
| 11.3.1 Coverage | 76 | 1 |
| 11.3.2 Secondary Research | 76 | 1 |
| 11.3.3 Primary Research | 76 | 1 |
| 11.3.4 Expert Panel Validation | 77 | 1 |
| 11.4 Contact Us | 77 | 1 |
| 11.5 Disclaimer | 77 | 1 |
| 11.6 Sources | 77 | 1 |